J
Jason Manro
Researcher at Eli Lilly and Company
Publications - 38
Citations - 1883
Jason Manro is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Cancer & T cell. The author has an hindex of 16, co-authored 35 publications receiving 1553 citations. Previous affiliations of Jason Manro include Pfizer.
Papers
More filters
Journal ArticleDOI
Developmental Expression of the Major Human Hepatic CYP3A Enzymes
Jeffrey C. Stevens,Ronald N. Hines,Chungang Gu,Sevasti B. Koukouritaki,Jason Manro,Peter J. Tandler,Matthew J. Zaya +6 more
TL;DR: The objective of this study was to characterize the developmental expression of hepatic CYP3A forms from early gestation to 18 years of age using up to 212 fetal and pediatric liver samples and based on immunoquantitation, CYP 3A5 protein expression was found to be highly variable, generally independent of age, and more frequently observed for African-American individuals.
Journal ArticleDOI
Developmental expression of human hepatic CYP2C9 and CYP2C19.
Sevasti B. Koukouritaki,Jason Manro,Sandra A. Marsh,Jeffrey C. Stevens,Allan E. Rettie,D. Gail McCarver,Ronald N. Hines +6 more
TL;DR: The ontogeny of CYP2C9 and -2C19 were dissimilar among both fetal and 0- to 5-months postnatal samples, implying different developmental regulatory mechanisms.
Journal ArticleDOI
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B. Holmgaard,David Schaer,Yanxia Li,Stephen Castaneda,Mary Murphy,Xiaohong Xu,Ivan Inigo,Julie Dobkin,Jason Manro,Philip W. Iversen,David Surguladze,Gerald Hall,Ruslan D. Novosiadly,Karim A. Benhadji,Gregory D. Plowman,Michael Kalos,Michael Kalos,Kyla Driscoll +17 more
TL;DR: Combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition and complete regressions in colon carcinoma models, demonstrating the potential synergy when cotargeting TGFβ and PD-1/PD- L1 pathways.
Journal ArticleDOI
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan,Victoria L. Peek,Rose T. Ajamie,Sean Buchanan,Jeremy R. Graff,Steven A. Heidler,Yu-Hua Hui,Karen L. Huss,Bruce W. Konicek,Jason Manro,Chuan Shih,Julie Stewart,Trent R. Stewart,Stephanie L. Stout,Mark T. Uhlik,Suzane L. Um,Yong Wang,Wenjuan Wu,Lei Yan,Wei J. Yang,Boyu Zhong,Richard A. Walgren +21 more
TL;DR: Preclinical development of a potent, orally bioavailable, small-molecule inhibitor LY2801653 targeting MET kinase is reported, currently in phase 1 clinical testing in patients with advanced cancer.
Journal ArticleDOI
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Jonathan Michael Yingling,William T. McMillen,Lei Yan,Huocong Huang,J. Scott Sawyer,Jeremy R. Graff,David K. Clawson,Karen S. Britt,Bryan D. Anderson,Douglas W. Beight,Durisala Desaiah,Michael Lahn,Karim A. Benhadji,Maria Jose Lallena,Rikke B. Holmgaard,Xiaohong Xu,Faming Zhang,Jason Manro,Philip W. Iversen,Chandrasekar V. Iyer,Rolf A. Brekken,Michael Kalos,Kyla Driscoll +22 more
TL;DR: It is demonstrated that galunisertib inhibits a number of TGFβ-dependent functions leading to anti-tumor activity, providing rationale for further informed clinical development of T GFβ pathway inhibitors.